Media stories about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive on Tuesday, AlphaOne Sentiment reports. The research group, a service of Accern, identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 0.12 on AlphaOne’s scale. AlphaOne also gave media coverage about the biopharmaceutical company an impact score of 83 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Alpha One’s scoring:
- 3 Value Stocks You Haven't Thought Of (finance.yahoo.com)
- Time to Reconsider Lexicon Pharmaceuticals Incorporated (NASDAQ:LXRX) After More Short Sellers? (upbeacon.net)
- ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017 (finance.yahoo.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Overview Of Different Chart Patterns: ACADIA Pharmaceuticals Inc. (ACAD), Inphi Corporation (IPHI) – AllStockNews (allstocknews.com)
Several research analysts have commented on ACAD shares. HC Wainwright restated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 17th. Rodman & Renshaw restated a “buy” rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Jefferies Group LLC restated a “buy” rating and issued a $47.00 target price on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 12th. Finally, ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $42.88.
Shares of ACADIA Pharmaceuticals (NASDAQ ACAD) opened at 27.99 on Tuesday. ACADIA Pharmaceuticals has a 12-month low of $20.68 and a 12-month high of $40.83. The stock’s market cap is $3.42 billion. The firm has a 50 day moving average price of $28.28 and a 200 day moving average price of $32.02.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.01. ACADIA Pharmaceuticals had a negative return on equity of 63.07% and a negative net margin of 948.93%. The company had revenue of $15.30 million during the quarter, compared to analyst estimates of $15.17 million. During the same period in the prior year, the company earned ($0.45) earnings per share. On average, equities analysts expect that ACADIA Pharmaceuticals will post ($2.83) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “ACADIA Pharmaceuticals (ACAD) Given Media Impact Score of 0.12” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2654392/acadia-pharmaceuticals-acad-given-media-impact-score-of-0-12.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.